Celldex Therapeutics (CLDX) risk factors, FY2024 10-K

Other

1. 01You should consider carefully these risk factors together with all of the information included or incorporated by reference in this Annual Report in addition to our financial statements and the notes to our financial statements. This section includes forward-looking statements

Risks Related to Our Financial Condition and Capital Requirements

1. 02We currently have no product revenue and will need to raise capital to operate our business
2. 03We expect to incur future losses and we may never become profitable
3. 04We will need additional capital to fund our operations, including the development, manufacture and potential commercialization of our drug candidates. If we do not have or cannot raise additional capital when needed, we may be unable to develop and ultimately commercialize our drug candidates successfully
4. 05Our stockholders may be subject to substantial dilution if we elect to pay future milestone consideration to the former Kolltan stockholders in shares of common stock. If we elect to pay future milestone consideration in cash, we would likely need to raise additional capital

Risks Related to Development and Regulatory Approval of Drug Candidates

1. 06Our long-term success depends heavily on our ability to fund and complete the research and development activities and obtain regulatory approval for our program assets
2. 07Our drug candidates are subject to extensive regulatory scrutiny
3. 08Premarket review of our product candidates by the FDA and/or other regulatory authorities is a lengthy and uncertain process and approval may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenues
4. 09If our drug candidates do not pass required tests for safety and effectiveness, we will not be able to obtain regulatory approval and derive commercial revenue from them
5. 10Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot assure you that any of the clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval
6. 11Product testing is critical to the success of our drug candidates but subject to delay or cancellation if we have difficulty enrolling patients
7. 12We may have delays in commencing, enrolling and completing our clinical trials, and we may not complete them at all
8. 13If serious adverse or unacceptable side effects are identified during the development of our drug candidates, such events could prevent us from obtaining regulatory approval or achieving market acceptance of our drug candidates, and we may need to abandon or limit our development of some of our drug candidates
9. 14We may expend our resources to pursue a particular drug candidate or indication and forgo the opportunity to capitalize on drug candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success
10. 15We may be unable to manage multiple late-stage clinical trials for a variety of drug candidates simultaneously
11. 16Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our drug candidates, if needed, could harm our drug development strategy and operational results
12. 17Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn future revenues

Risks Related to Commercialization of Our Drug Candidates

1. 18We may face delays, difficulties or unanticipated costs in establishing sales, marketing and distribution capabilities or seeking a partnership for the commercialization of our drug candidates, even if regulatory approval is obtained
2. 19If our drug candidates for which we obtain regulatory approval do not achieve broad acceptance from physicians, patients and third-party payors, we may be unable to generate significant revenues, if any
3. 20Even if any of our drug candidates receive FDA approval, the terms of the approval may limit such drug’s commercial potential. Additionally, even after receipt of FDA approval, such drug would be subject to substantial, ongoing regulatory requirements
4. 21Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance of any of our drug candidates. If there is not sufficient reimbursement for our future drugs, it is less likely that such drugs will be widely used
5. 22Other factors could affect the demand for and sales and profitability of any drug candidates that we may commercialize in the future
6. 23Failure to obtain regulatory approvals in foreign jurisdictions will prevent us from marketing our products internationally
7. 24Before granting the MA, the European Medicines Agency or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy
8. 25If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
9. 26The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges

Risks Related to Reliance on Third Parties

1. 27We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product development
2. 28We rely on CDMOs over whom we have limited control. Should the cost, delivery and quality of clinical materials manufactured by us in our Fall River facility or supplied by CDMOs vary to our disadvantage, our business operations could suffer significant harm
3. 29We may need to rely on third-party collaborators to develop and commercialize companion diagnostic tests for our drug candidates
4. 30Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them

Risks Related to Business Operations

1. 31We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
2. 32We may expand our clinical development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 33We may not be able to successfully integrate our existing technology or to modify our technologies to create new immunotherapeutic drugs
4. 34Our internal computer systems, or those of our CROs, CDMOs, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development programs
5. 35Our business requires us to use hazardous materials, which increases our exposure to dangerous and costly accidents
6. 36We face the risk of product liability claims, which could exceed our insurance coverage, and product recalls, each of which could deplete our cash resources
7. 37Product liability claims can be expensive to defend, even if the drug or drug candidate did not actually cause the alleged injury or harm

Risks Related to Intellectual Property

1. 38Our ability to successfully develop and, if regulatory approval is obtained, commercialize our drug candidates may be materially adversely affected if we are unable to obtain and maintain effective intellectual property rights for our drug candidates and technologies
2. 39We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms
3. 40We may be unable to protect the confidentiality of our trade secrets, thus harming our business and competitive position
4. 41We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time- consuming and unsuccessful
5. 42Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
6. 43Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets

Regulatory Risks

1. 44We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates
2. 45Any breakthrough therapy designation granted by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval
3. 46If our processes and systems are not compliant with regulatory requirements, we could be subject to delays in submitting BLAs, NDAs or restrictions on marketing of drugs after they have been approved
4. 47We have conducted and are conducting clinical trials outside the United States and anticipate conducting additional clinical trials outside the United States, and the FDA may not accept data from such trials
5. 48Changes in product candidate manufacturing or formulation may result in additional costs or delay
6. 49Even if we receive regulatory approval for a drug candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements
7. 50We may be subject, directly or indirectly, to federal and state health care fraud and abuse laws, false claims laws, transparency and pricing laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
8. 51Compliance with laws and regulations pertaining to the privacy and security of health information may be time consuming, difficult and costly, particularly in light of increased focus on privacy issues in countries around the world, including the U.S. and the EU
9. 52Changes in health care law and implementing regulations, including government restrictions on pricing and reimbursement, as well as health care policy and other health care payor cost-containment initiatives, may have a material adverse effect on us
10. 53Other examples of proposed changes include, but are not limited to, expanding post-approval requirements, changing the Orphan Drug Act, and restricting sales and promotional activities for pharmaceutical products

Risks Related to Our Capital Stock

1. 54Our history of losses and uncertainty of future profitability make our common stock a highly speculative investment
2. 55Our share price has been and could remain volatile
3. 56Our ability to use our net operating loss carryforwards will be subject to limitation and, under certain circumstances, may be eliminated
4. 57We have many competitors in our field, and they may develop technologies that make ours obsolete
5. 58We or the third parties upon whom we depend may be adversely affected by natural disasters or other unforeseen events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
6. 59We face risks related to health epidemics and outbreaks, which could significantly disrupt our preclinical studies and clinical trials
7. 60Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations
8. 61We depend greatly on the intellectual capabilities and experience of our key executives and scientists, and the loss of any of them could affect our ability to develop our products
9. 62Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
10. 63We may not be able to maintain compliance with the Listing Rules of the NASDAQ Stock Exchange